DBV Technologies S.A.
DBV Technologies S.A. (DBVT): 41 pipeline candidates · 3 upcoming catalysts · ~14 mo cash runway · 22 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
14.3 months
D/E 0.28
Lead: Approved
41 candidates
3 upcoming, next in ~683d
0 buys · 1 sell (180d)
A transparent, data-derived signal for DBV Technologies S.A.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$991.4M
Cash
$229.2M
Quarterly Burn
$49.1M
Runway
14.3 mo
Revenue
$900K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (41 candidates)
| Drug | Phase |
|---|---|
| buprenorphine | Approved |
| cdz173 | Phase 2/Phase 3 |
| clonidine | Approved |
| dbv712 | Phase 3 |
| dbv712 | Phase 3 |
| dbv712 | Phase 3 |
| dbv712 | Phase 3 |
| dbv712 | Phase 3 |
| dbv712 | Phase 3 |
| dbv712 | Phase 3 |
Showing 10 of 41 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
66
Total value held
$275.8M
| Holder | Shares | Value |
|---|---|---|
| mpm bioimpact llc | 5,213,361 | $108.9M |
| perceptive advisors llc | 1,928,782 | $40.3M |
| baker bros. advisors lp | 1,461,425 | $30.5M |
| adar1 capital management, llc | 1,012,866 | $21.2M |
| redmile group, llc | 491,340 | $10.3M |
| millennium management llc | 318,959 | $6.7M |
| atika capital management llc | 271,300 | $5.7M |
| elmind capital, lp | 265,000 | $5.5M |
| balyasny asset management l.p. | 233,429 | $4.9M |
| ameriprise financial inc | 231,417 | $4.8M |
Showing top 10 of 66 institutional holders of DBV Technologies S.A.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in DBV Technologies S.A.'s pipeline?
DBV Technologies S.A. (DBVT) has 41 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is DBV Technologies S.A.'s lead drug candidate?
DBV Technologies S.A.'s most advanced tracked candidate is buprenorphine (Approved).
What is DBV Technologies S.A.'s next catalyst?
DBV Technologies S.A.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous I" — expected May 1, 2028.
What is DBV Technologies S.A.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, DBV Technologies S.A. has approximately 14.3 months of cash runway.
What is DBV Technologies S.A.'s market capitalization?
DBV Technologies S.A.'s market capitalization is approximately $991.4M.
Get the full picture on DBV Technologies S.A.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.